Method of reducing neuronal cell death with haloalkylamines

Abstract

The present invention is directed to pharmaceutical compositions and methods of treating traumatic brain injury (TBI). The invention is also directed to pharmaceutical compositions and methods of treating a transient hypoxic and/or ischemic condition in the central nervous system. More specifically, the present invention is directed to pharmaceutical compositions and methods of reducing the occurrence of nerounal cell death in the centeral nervous system, such as, reducing the occurrence brain cell death in the hippocampus and/or the cortex.

1 - 39 . (canceled) 
     
     
         40 . A method of inhibiting neuronal cell death in a subject that is caused by a traumatic brain injury (TBI) event, the method comprising administering to the subject a pharmaceutical composition comprising phenoxybenzamine or a salt thereof in an amount sufficient to reduce neuronal cell death in the central nervous system of the subject. 
     
     
         41 . The method of  claim 40 , further comprising determining that the subject has had a TBI event and is at risk of neuronal cell death, wherein the TBI event is selected from the group consisting of whiplash, a blast wave impact, and blunt force trauma. 
     
     
         42 . The method of  claim 40 , wherein the pharmaceutical composition comprising phenoxybenzamine or salt thereof is administered in a single dose. 
     
     
         43 . The method according to  claim 40 , wherein the phenoxybenzamine or salt thereof is in unit dosage amounts of about 0.5 mg/kg body weight to about 20 mg/kg body weight. 
     
     
         44 . The method according to  claim 40 , wherein the pharmaceutical composition comprising phenoxybenzamine or salt thereof is administered with a pharmaceutically acceptable carrier. 
     
     
         45 . The method according to  claim 40 , wherein the pharmaceutical composition comprising phenoxybenzamine or a salt thereof is in an extended release formulation. 
     
     
         46 . The method according to  claim 41 , wherein the pharmaceutical composition comprising phenoxybenzamine or a salt thereof is administered within 24 hours after onset of the TBI event. 
     
     
         47 . The method according to  claim 41 , wherein the pharmaceutical composition comprising phenoxybenzamine or a salt thereof is administered within 18 hours after onset of the TBI event. 
     
     
         48 . The method according to  claim 41 , wherein the pharmaceutical composition comprising phenoxybenzamine or a salt thereof is administered in a single dose within 16 hours after onset of the TBI event. 
     
     
         49 . The method according to  claim 40 , wherein the administering is via an intravenous injection.